Company intelligence / Profile preview
Psyence Biomedical Ltd.
- Ownership
- Public · PBM
- Development stage
- Other
Overview
Psyence Biomedical’s lead candidate PEX010—a naturally sourced psilocybin capsule—is currently being evaluated in a randomized, double-blind Phase IIb study targeting adjustment disorder with anxiety/depression following advanced cancer diagnosis within the context of palliative care. The trial will test three doses of natural psilocybin combined with psychotherapy across multiple sites. Topline data are expected by the second half of 2025. If positive, results will support initiation of pivotal registrational studies shortly thereafter.
- Therapeutic areas
- Psychiatry
- Modalities
- Botanical/nature-derived psilocybin (psychedelic small molecule)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Financials
- Market cap
- $55.9K
- Total revenue
- $0
- Enterprise value
- $-7.1M
Beyond the preview
Go deeper on Psyence Biomedical Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Psyence Biomedical Ltd..